Article

AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.

Bio Nano Electronics Research Center, Graduate School of Interdisciplinary New Science, Toyo University Kawagoe, Saitama 350-8585, Japan
Biotechnology and Bioengineering (Impact Factor: 4.16). 05/2012; 109(11):2920-31. DOI: 10.1002/bit.24558
Source: PubMed

ABSTRACT Liposomes and polymers are widely used drug carriers for controlled release since they offer many advantages like increased treatment effectiveness, reduced toxicity and are of biodegradable nature. In this work, anticancer drug-loaded PLGA-lecithin-PEG nanoparticles (NPs) were synthesized and were functionalized with AS1411 anti-nucleolin aptamers for site-specific targeting against tumor cells which over expresses nucleolin receptors. The particles were characterized by transmission electron microscope (TEM) and X-ray photoelectron spectroscopy (XPS). The drug-loading efficiency, encapsulation efficiency and in vitro drug release studies were conducted using UV spectroscopy. Cytotoxicity studies were carried out in two different cancer cell lines, MCF-7 and GI-1 cells and two different normal cells, L929 cells and HMEC cells. Confocal microscopy and flowcytometry confirmed the cellular uptake of particles and targeted drug delivery. The morphology analysis of the NPs proved that the particles were smooth and spherical in shape with a size ranging from 60 to 110 nm. Drug-loading studies indicated that under the same drug loading, the aptamer-targeted NPs show enhanced cancer killing effect compared to the corresponding non-targeted NPs. In addition, the PLGA-lecithin-PEG NPs exhibited high encapsulation efficiency and superior sustained drug release than the drug loaded in plain PLGA NPs. The results confirmed that AS1411 aptamer-PLGA-lecithin-PEG NPs are potential carrier candidates for differential targeted drug delivery. Biotechnol. Bioeng. 2012; 109: 2920-2931. © 2012 Wiley Periodicals, Inc.

1 Bookmark
 · 
369 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Targeted drug delivery coupled with rapid drug release in cytoplasm is a powerful strategy to enhance efficacy and reduce off-target effects of anti-cancer drugs. Herein, we describe a dual-functional mixed micellar system consisting of a pH-responsive copolymer D-α-tocopheryl polyethylene glycol 1000-block-poly-(β-amino ester) (TPGS-b-PBAE, TP) and AS1411 aptamer (Apt) decorated TPGS polymer (Apt-TPGS), which recognizes the over-expressed nucleolin on the plasma membrane of cancer cells. The anti-cancer drug paclitaxel (PTX) was encapsulated in the Apt-mixed micelles, and these drug-loaded micelles had a suitable particle size and zeta potential of 116.3 nm ± 12.4 nm and −26.2 mV ±4.2 mV, respectively. PTX/Apt-mixed micelles were stable at pH 7.4, but they dissociated and quickly released the encapsulated PTX in a weakly acidic environment (pH 5.5). Compared with non-Apt modified mixed micelles, more Apt-modified mixed micelles were internalized in SKOV3 ovarian cancer cells, whereas no significant difference in cellular uptake was observed in normal cells (LO2 cells). The enhanced transmembrane ability of Apt-modified mixed micelles was achieved through Apt-nucleolin interaction. With a synergistic effect of cancer cell recognition and pH-sensitive drug release, we observed significantly increased cytotoxicity and G2/M phase arrest against SKOV3 cells by PTX/Apt-mixed micelles. Intravenous administration of PTX/Apt-mixed micelles for 16 days significantly increased tumor accumulation of PTX, inhibited tumor growth, and reduced myelosuppression on tumor-bearing mice compared with free PTX injection. Therefore, this dual-functional Apt-mixed micellar system is a promising drug delivery system for targeted cancer therapy.
    Nano Research 01/2015; DOI:10.1007/s12274-014-0619-4 · 6.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent research in chemotherapy has prioritized overcoming the multidrug resistance (MDR) of cancer cells. In this work, liposomes that contain doxorubicin (DOX) and ammonium bicarbonate (ABC, a bubble-generating agent) are prepared and functionalized with an antinucleolin aptamer (AS1411 liposomes) to target DOX-resistant breast cancer cells (MCF-7/ADR), which overexpress nucleolin receptors. Free DOX and liposomes without functionalization with AS1411 (plain liposomes) were used as controls. The results of molecular dynamic simulations suggest that AS1411 functionalization may promote the affinity and specific binding of liposomes to the nucleolin receptors, enhancing their subsequent uptake by tumor cells, whereas plain liposomes enter cells with difficulty. Upon mild heating, the decomposition of ABC that is encapsulated in the liposomes enables the immediate activation of generation of CO2 bubbles, creating permeable defects in their lipid bilayers, and ultimately facilitating the swift intracellular release of DOX. In vivo studies in nude mice that bear tumors demonstrate that the active targeting of AS1411 liposomes can substantially increase the accumulation of DOX in the tumor tissues relative to free DOX or passively targeted plain liposomes, inhibiting tumor growth and reducing systemic side effects, including cardiotoxicity. The above findings indicate that liposomes that are functionalized with AS1411 represent an attractive therapeutic alternative for overcoming the MDR effect, and support a potentially effective strategy for cancer therapy. Copyright © 2015. Published by Elsevier B.V.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pancreatic cancer is the fifth leading cause of cancer related deaths worldwide. Currently, finding an effective drug delivery strategy in pancreatic cancer treatment is a major challenge. Nanotechnology offers an indispensible function by precisely delivering anticancer therapeutics in a targeted method to the cancer specific cells thus sparing normal healthy cells and hence resulting in an enhanced efficiency. The development of designer multifunctional therapeutics with magnetic nanoparticles (MNP) is a promising approach to selectively deliver therapeutics and image them in cancer cells. This study explored the preparation, characterization and application of a targeted nanosystem represented by an aptamer conjugated dual drug (curcumin and gemcitabine-loaded) and MNP encapsulated PLGA nanoparticles (Apt-Cur-Gem-PLGA-MNPs) for pancreatic cancer therapy. The aptamer targeted NPs exhibited excellent antiproliferative activity leading to apoptosis owing to enhanced cellular uptake. The presence of MNP in the nanoconjugate was exploited for magnetic hyperthermia and magnetic ablation of cancer cells by a rotating magnetic field. Thus, Apt-Cur-Gem-PLGA-MNPs is able to deliver an effective and targeted delivery of therapeutics for pancreatic cancer treatment.
    RSC Advances 01/2013; 3(43):20579. DOI:10.1039/c3ra42645a · 3.71 Impact Factor